Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $72000.0.

  • Catalyst Pharmaceuticals' Depreciation & Amortization (CF) fell 3207.55% to $72000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $417000.0, marking a year-over-year increase of 1362.4%. This contributed to the annual value of $397000.0 for FY2024, which is 2563.29% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Depreciation & Amortization (CF) is $72000.0, which was down 3207.55% from $116000.0 recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $116000.0 during Q2 2025, with a 5-year trough of $31000.0 in Q2 2021.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Depreciation & Amortization (CF) value was $81000.0 (recorded in 2023), while the average stood at $71000.0.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 59285.71% in 2021, then tumbled by 6494.85% in 2022.
  • Over the past 5 years, Catalyst Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $33000.0 in 2021, then rose by 6.06% to $35000.0 in 2022, then surged by 140.0% to $84000.0 in 2023, then surged by 35.71% to $114000.0 in 2024, then tumbled by 36.84% to $72000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $72000.0 in Q3 2025, compared to $116000.0 in Q2 2025 and $115000.0 in Q1 2025.